Universitätsmedizin Mainz
Universitätsmedizin Mainz
Mainz, Rhineland-Palatinate, Germany4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, skin disorder, skin neoplasm, viral infectious disease | Recruiting | Phase 2 | 2026-06-22 | NCT07387198 | |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Anal Cancer Metastatic; Pancreatic Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Unresectable Pancreatic Carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-19 | NCT07280377 | |
| Global Research Initiative for Patients Screening on MASH | Body Weight, Digestive System Diseases, Fibrosis, Fibrosis, Liver, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Steatohepatitis, cardiovascular disorder, cirrhosis of liver, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, hyperinsulinism, hypertensive disorder, liver disorder, metabolic disease, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, vascular disorder | Recruiting | Not stated | 2024-08-01 | NCT05651724 |